T1612

Neostigmine methyl sulfate (Syntostigmin) is a reversible inhibitor of acetylcholinesterase, can not cross the blood-brain barrier, used in the treatment of myasthenia gravis.

MPI_5a is a small molecule inhibitor and a highly selective HDAC6 inhibitor (IC50=36 nM). The IC50 value for MPI_5a inhibition of intracellular acetylated tubulin accumulation is 210 nM, used for HDAC6 function research.

Monepantel (AAD1566) is an organic anthelmintic and nicotinic acetylcholine receptor antagonist from roundworms and esophagostomies that is widely used for de-worming in agriculture and livestock.

MLT-748 is a MALT1 allosteric inhibitor that inhibits the growth of lung cancer cells. MLT-748 acts by blocking the protein hydrolyzing activity of MALT1.

MMAF Hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Hydrochloride is an effective tubulin polymerization inhibitor and is used as an antitumor compound.

MMAF sodium is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF sodium is an effective tubulin polymerization inhibitor and is used as an antitumor agent.

MMG-11 inhibits both TLR2/1 and TLR2/6 signaling (IC50s: 1.7 μM for Pam3CSK4-induced hTLR2/1 and 5.7 μM for Pam2CSK4-induced hTLR2/6 responses). MMG-11 is an effective and selective human TLR2 antagonist with low cytotoxicity.

MMP13-IN-3 is >1000 selective over other MMPs. MMP13-IN-3 is an effective, selective, and orally active MMP-13 inhibitor (IC50=1 nM) for the potential treatment of osteoarthritis.

MMV390048 is an antimalarial agent and is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kdapp=0.3 μM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns.

MP-A08 is a highly selective, ATP-competitive inhibitor of sphingosine kinase (SPHK1) that targets both SphK1 and SphK2 [Ki: 6.9 ± 0.8 μM and 27 ± 3 μM, respectively].